Cancer Medicine (Jul 2023)

Chemokines as possible therapeutic targets in metastatic melanoma

  • Charlise Basson,
  • June Cheptoo Serem,
  • Priyesh Bipath,
  • Yvette Nkondo Hlophe

DOI
https://doi.org/10.1002/cam4.6055
Journal volume & issue
Vol. 12, no. 13
pp. 14387 – 14402

Abstract

Read online

Abstract Background Cutaneous melanoma is a relentless form of cancer which continues to rise in incidence. Currently, cutaneous melanoma is the leading cause of skin cancer‐related mortality, which can mainly be attributed to its metastatic potential. The activation of chemokine axes is a major contributor to melanoma metastasis through its involvement in promoting tumour cell migration, proliferation, survival, and adhesion. This review will focus on the role of chemokines in melanoma and possible therapeutic strategies to alter chemokine activation and subsequently inhibit the activation of signalling cascades that may promote metastasis. Methods A literature review was conducted to evaluate chemokines as possible therapeutic targets in metastatic melanoma. Results The crosstalk between signalling pathways and immune responses in the melanoma microenvironment resembles a complex and dynamic system. Therefore, the involvement of governing chemokine axes in the promotion of cutaneous and metastatic melanoma demands a proper understanding of the tumour microenvironment in order to identify possible targets and develop appropriate treatments against melanoma. Conclusion Even though chemokine axes are regarded as promising therapeutic targets, it has become increasingly evident that chemokines can play a critical role in both tumour inhibition and promotion. The inhibition of chemokine axes to inhibit signalling cascades in target cells that regulate metastasis should, therefore, be carefully approached.

Keywords